Apr 05, 2024
KRAS mutations represent the most commonly encountered driver oncogene, implicated in approximately 25% of all human cancers, with KRASG12D emerging as a predominant isoform, particularly prevalent in pancreatic, colorectal, and non-small cell lung cancers. Despite its frequency, targeting KRASG12D poses distinct c...
Read More...
Apr 14, 2023
The upcoming AACR 2023 Annual Meeting will have a range of abstracts, including regular abstracts, clinical trials, and late-breaking abstracts. Among the abstracts being presented at the conference, we have listed a few potential abstracts, which we have listed in the below table. The table includes information ab...
Read More...
The Next Wave of Radioligand Therapies: 5 Candidates to Watch
Mar 20, 2026
Emerging TIL Therapies Poised to Broaden the Landscape Beyond AMTAGVI
Mar 06, 2026
BYSANTI Approval Positions Vanda to Compete in the Antipsychotic Market
Mar 02, 2026
Newsletter/Whitepaper